https://mindmedicinelaw.com/briefing/bridging-efficacy-and-real-world-practice-in-psychedelic-trials-20261030-55107The Psychedelic Journalen2026-10-30T22:05:37.144623+00:00Bridging Efficacy and Real-World Practice in Psychedelic Trialspsychedelic clinical trials, real-world effectiveness, psilocybin therapy, mdma-assisted therapy, fda regulation, payer adoption, implementation science, oregon psilocybin program, integration support, trial designhttps://mindmedicinelaw.com/briefing/psilocybin-s-multi-scale-brain-effects-in-macaques-translational-insights-20261029-55028The Psychedelic Journalen2026-10-30T22:07:12.002799+00:00Psilocybin’s Multi-Scale Brain Effects in Macaques: Translational Insightspsilocybin, non-human primate research, macaque brain, translational neuroscience, clinical trial design, fda regulatory review, neuroimaging, preclinical models, psychedelic safetyhttps://mindmedicinelaw.com/briefing/psychedelics-and-disorders-of-consciousness-trial-design-challenges-in-the-us-an-20261029-55106The Psychedelic Journalen2026-10-30T22:06:57.926373+00:00Psychedelics and Disorders of Consciousness: Trial Design Challenges in the US and EUpsychedelic clinical trials, disorders of consciousness, trial design challenges, fda guidance, surrogate consent, neuroimaging endpoints, ethical issues, regulatory barriers, psilocybin research, dmt trialshttps://mindmedicinelaw.com/briefing/virtual-reality-integration-in-ketamine-therapy-us-chart-review-insights-20261029-55109The Psychedelic Journalen2026-10-30T22:06:40.576721+00:00Virtual Reality Integration in Ketamine Therapy: US Chart Review Insightsvirtual reality, ketamine therapy, psychedelic-assisted therapy, digital therapeutics, retrospective chart review, clinical protocols, FDA regulation, tolerability, mental health innovationhttps://mindmedicinelaw.com/briefing/psychedelics-for-substance-use-disorders-evidence-mechanisms-and-gaps-20261029-55027The Psychedelic Journalen2026-10-30T22:05:52.342207+00:00Psychedelics for Substance Use Disorders: Evidence, Mechanisms, and Gapspsychedelics, substance use disorder, psilocybin, clinical trials, neuroplasticity, ibogaine, ketamine, addiction treatment, policy, mechanismshttps://mindmedicinelaw.com/briefing/deep-brain-stimulation-for-anorexia-nervosa-efficacy-targets-and-challenges-20261028-55031The Psychedelic Journalen2026-10-30T22:07:42.964765+00:00Deep Brain Stimulation for Anorexia Nervosa: Efficacy, Targets, and Challengesdeep brain stimulation, anorexia nervosa, treatment-resistant, neuroanatomical targets, connectome-guided neuromodulation, clinical trials, ethical challenges, ai-assisted neuromodulation, device regulationhttps://mindmedicinelaw.com/briefing/torpor-depression-link-implications-for-neuroscience-and-trials-20261028-55046The Psychedelic Journalen2026-10-30T22:07:27.792988+00:00Torpor-Depression Link: Implications for Neuroscience and Trialstorpor, depressive disorders, animal models, clinical trial design, psychedelic research, circadian biology, neuroplasticity, translational neuroscience, biomarkers, regulatory implicationshttps://mindmedicinelaw.com/briefing/controlled-vs-naturalistic-dosing-in-cannabis-research-evolving-standards-20261028-54914The Psychedelic Journalen2026-10-30T15:06:10.409021+00:00Controlled vs. Naturalistic Dosing in Cannabis Research: Evolving Standardscannabis research, controlled dosing, naturalistic studies, clinical trial design, regulatory science, public health policy, thc potency, hybrid study methods, fda guidance, market regulationhttps://mindmedicinelaw.com/briefing/ai-driven-multimodal-depression-detection-implications-for-psychedelic-trials-20261028-54658The Psychedelic Journalen2026-10-29T15:08:21.397363+00:00AI-Driven Multimodal Depression Detection: Implications for Psychedelic Trialsai depression detection, multimodal diagnostics, psychedelic clinical trials, explainable ai, directional causal fusion, digital health regulation, biometric monitoring, patient selection, mental health technologyhttps://mindmedicinelaw.com/briefing/psilocybin-retreats-connectedness-and-wellbeing-insights-for-public-health-polic-20261028-54657The Psychedelic Journalen2026-10-29T15:07:22.882216+00:00Psilocybin Retreats, Connectedness, and Wellbeing: Insights for Public Health Policypsilocybin retreats, connectedness, mental wellbeing, psychedelic research, public health policy, naturalistic study, integration, regulatory implications, mystical experienceshttps://mindmedicinelaw.com/briefing/genome-analysis-of-gymnopilus-dilepis-illuminates-psilocybin-pathways-20261028-54659The Psychedelic Journalen2026-10-29T15:07:06.122978+00:00Genome Analysis of Gymnopilus dilepis Illuminates Psilocybin Pathwayspsilocybin biosynthesis, gymnopilus dilepis genome, synthetic biology, amino acid metabolism, psychedelic research, clinical supply chain, metabolic engineering, regulatory sciencehttps://mindmedicinelaw.com/briefing/topical-ketamine-for-oral-mucositis-pain-evidence-and-gaps-in-cancer-care-20261027-54706The Psychedelic Journalen2026-10-29T15:07:48.084089+00:00Topical Ketamine for Oral Mucositis Pain: Evidence and Gaps in Cancer Caretopical ketamine, oral mucositis, chemotherapy pain, opioid-sparing, supportive cancer care, randomized controlled trials, adverse events, dosing variability, pediatric oncology, regulatory approvalhttps://mindmedicinelaw.com/briefing/low-dose-ketamine-modulates-brain-entropy-in-trd-neuroimaging-evidence-20261026-55055The Psychedelic Journalen2026-10-30T22:06:08.114135+00:00Low-Dose Ketamine Modulates Brain Entropy in TRD: Neuroimaging Evidenceketamine, brain entropy, treatment-resistant depression, neuroimaging, biomarkers, psychedelic therapy, clinical trials, mechanism of action, rapid antidepressant, translational neurosciencehttps://mindmedicinelaw.com/briefing/feasibility-of-psychedelic-like-vr-for-ocd-multicentre-study-in-germany-and-ital-20261026-54698The Psychedelic Journalen2026-10-29T15:08:03.573790+00:00Feasibility of Psychedelic-Like VR for OCD: Multicentre Study in Germany and Italyvirtual reality, psychedelic therapy, obsessive-compulsive disorder, digital therapeutics, clinical trials, psychological flexibility, non-pharmacological interventions, regulatory implications, cybersickness, ego dissolutionhttps://mindmedicinelaw.com/briefing/india-s-first-public-interventional-psychiatry-service-integrates-psychedelic-th-20261023-55001The Psychedelic Journalen2026-10-30T22:06:25.460169+00:00India’s First Public Interventional Psychiatry Service Integrates Psychedelic Therapiesinterventional psychiatry, psychedelic therapy, india public health, neuromodulation, teaching hospital, clinical integration, regulatory policy, mental health innovation, low- and middle-income countrieshttps://mindmedicinelaw.com/briefing/control-conditions-in-ivr-trials-implications-for-psychedelic-research-20261023-54699The Psychedelic Journalen2026-10-29T15:09:19.030385+00:00Control Conditions in IVR Trials: Implications for Psychedelic Researchivr control conditions, virtual placebo, psychedelic research, clinical trial design, digital therapeutics, randomized controlled trials, methodological rigor, fda guidance, mental health interventionshttps://mindmedicinelaw.com/briefing/bias-aware-meta-analysis-method-advances-psychedelic-research-synthesis-20261023-54700The Psychedelic Journalen2026-10-29T15:08:58.186175+00:00Bias-Aware Meta-Analysis Method Advances Psychedelic Research Synthesisbias-aware meta-analysis, psychedelic research, evidence synthesis, heterogeneous studies, clinical trials, regulatory policy, reproducibility, statistical methods, fixed-effect model, random-effects modelhttps://mindmedicinelaw.com/briefing/mri-guided-reverse-translational-framework-in-psychiatry-research-20261023-54714The Psychedelic Journalen2026-10-29T15:08:37.700319+00:00MRI-Guided Reverse-Translational Framework in Psychiatry Researchmri volumetric analysis, reverse translation, psychiatric research, animal models, psychedelic mechanisms, clinical trial design, brain structure, translational neurosciencehttps://mindmedicinelaw.com/briefing/psilocybin-s-biological-effects-in-parkinson-s-early-clinical-trial-insights-20261021-54989The Psychedelic Journalen2026-10-30T15:05:52.728632+00:00Psilocybin’s Biological Effects in Parkinson’s: Early Clinical Trial Insightspsilocybin, parkinson's disease, inflammation markers, mitochondrial stress, clinical trial, neurodegeneration, biomarkers, policy implications, mechanistic research